PE-CycleGAN network based CBCT-sCT generation for nasopharyngeal carsinoma adaptive radiotherapy.
10.12122/j.issn.1673-4254.2025.01.21
- Author:
Yadi HE
1
;
Xuanru ZHOU
1
;
Jinhui JIN
1
;
Ting SONG
1
Author Information
1. School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
adaptive radiotherapy;
cone-beam CT;
deep learning;
generative adversarial network;
synthetic CT images
- MeSH:
Humans;
Cone-Beam Computed Tomography/methods*;
Nasopharyngeal Neoplasms/diagnostic imaging*;
Nasopharyngeal Carcinoma/radiotherapy*;
Radiotherapy Planning, Computer-Assisted/methods*;
Radiotherapy Dosage;
Signal-To-Noise Ratio;
Radiotherapy, Intensity-Modulated
- From:
Journal of Southern Medical University
2025;45(1):179-186
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To explore the synthesis of high-quality CT (sCT) from cone-beam CT (CBCT) using PE-CycleGAN for adaptive radiotherapy (ART) for nasopharyngeal carcinoma.
METHODS:A perception-enhanced CycleGAN model "PE-CycleGAN" was proposed, introducing dual-contrast discriminator loss, multi-perceptual generator loss, and improved U-Net structure. CBCT and CT data from 80 nasopharyngeal carcinoma patients were used as the training set, with 7 cases as the test set. By quantifying the mean absolute error (MAE), peak signal-to-noise ratio (PSNR), structural similarity index (SSIM), as well as the dose gamma pass rate and the relative dose deviations of the target area and organs at risk (OAR) between sCT and reference CT, the image quality and dose calculation accuracy of sCT were evaluated.
RESULTS:The MAE of sCT generated by PE-CycleGAN compared to the reference CT was (56.89±13.84) HU, approximately 30% lower than CBCT's (81.06±15.86) HU (P<0.001). PE-CycleGAN's PSNR and SSIM were 26.69±2.41dB and 0.92±0.02 respectively, significantly higher than CBCT's 21.54±2.37dB and 0.86±0.05 (P<0.001), indicating substantial improvements in image quality and structural similarity. In gamma analysis, under the 2 mm/2% criterion, PE-CycleGAN's sCT achieved a pass rate of (90.13±3.75)%, significantly higher than CBCT's (81.65±3.92)% (P<0.001) and CycleGAN's (87.69±3.50)% (P<0.05). Under the 3 mm/3% criterion, PE-CycleGAN's sCT pass rate of (90.13±3.75)% was also significantly superior to CBCT's (86.92±3.51)% (P<0.001) and CycleGAN's (94.58±2.23)% (P<0.01). The mean relative dose deviation of the target area and OAR between sCT and planned CT was within ±3% for all regions, except for the Lens Dmax (Gy), which had a deviation of 3.38% (P=0.09). The mean relative dose deviations for PTVnx HI, PTVnd HI, PTVnd CI, PTV1 HI, PRV_SC, PRV_BS, Parotid, Larynx, Oral, Mandible, and PRV_ON were all less than ±1% (P>0.05).
CONCLUSIONS:PE-CycleGAN demonstrates the ability to rapidly synthesize high-quality sCT from CBCT, offering a promising approach for CBCT-guided adaptive radiotherapy in nasopharyngeal carcinoma.
